FY2027 EPS Estimates for Prothena Cut by HC Wainwright

Prothena Co. plc (NASDAQ:PRTA) – Analysts at HC Wainwright lowered their FY2027 earnings per share (EPS) estimates for shares of Prothena in a note issued to investors on Tuesday, May 27th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will earn ($5.44) per share for the year, down from their previous estimate of ($4.70). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share. HC Wainwright also issued estimates for Prothena’s FY2028 earnings at ($2.73) EPS and FY2029 earnings at ($3.56) EPS.

Other research analysts have also issued reports about the stock. Jefferies Financial Group lowered shares of Prothena from a “buy” rating to a “hold” rating and set a $6.00 target price on the stock. in a research note on Tuesday. Wall Street Zen upgraded Prothena from a “sell” rating to a “hold” rating in a research report on Monday, February 24th. Bank of America reissued an “underperform” rating on shares of Prothena in a research note on Wednesday. Chardan Capital cut their target price on Prothena from $40.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Piper Sandler reduced their price target on Prothena from $110.00 to $81.00 and set an “overweight” rating on the stock in a report on Tuesday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Prothena has an average rating of “Hold” and a consensus target price of $31.50.

Prothena Trading Down 2.3%

PRTA opened at $4.59 on Thursday. Prothena has a twelve month low of $4.32 and a twelve month high of $25.42. The firm has a market capitalization of $247.07 million, a PE ratio of -2.00 and a beta of 0.11. The firm’s 50-day moving average price is $8.88 and its 200 day moving average price is $12.48.

Prothena (NASDAQ:PRTA) last released its earnings results on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.20). The business had revenue of $2.83 million for the quarter, compared to analysts’ expectations of $8.18 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. Prothena’s quarterly revenue was up 5500.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.34) EPS.

Hedge Funds Weigh In On Prothena

Several large investors have recently modified their holdings of PRTA. Virtus ETF Advisers LLC lifted its position in Prothena by 19.3% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 833 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Prothena by 4,626.0% in the 1st quarter. GAMMA Investing LLC now owns 6,002 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 5,875 shares during the last quarter. Headlands Technologies LLC lifted its holdings in shares of Prothena by 196.5% in the 4th quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 4,858 shares during the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Prothena during the 1st quarter worth approximately $126,000. Finally, Teacher Retirement System of Texas acquired a new stake in Prothena in the 4th quarter valued at approximately $145,000. Institutional investors and hedge funds own 97.08% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.